特殊护理 nurseries 中新生儿经鼻高流量治疗
该多中心、随机、非劣效性试验纳入澳大利亚特殊护理 nurseries 中年龄<24小时、胎龄≥31周、呼吸窘迫且出生体重≥1200g的新生儿,随机接受经鼻高流量治疗或CPAP,主要终点为随机化后72小时内治疗失败。意向性治疗分析显示,高流量组381例中78例(20.5%)治疗失败,CPAP组373例中38例(10.2%)治疗失败,风险差10.3个百分点(95%CI 5.2至15.4),超过10个百分点的非劣效界值。符合方案分析中高流量组339例中49例(14.5%)失败,CPAP组338例中27例(8.0%)失败,风险差6.5个百分点(95%CI 1.7至11.2)。机械通气发生率、转至三级新生儿重症监护病房发生率及不良事件两组无显著差异。
要点
- 在非三级特殊护理 nurseries 中,呼吸窘迫新生儿(胎龄≥31周、出生体重≥1200g、年龄<24小时)早期使用经鼻高流量治疗,72小时内治疗失败率20.5%(78/381),CPAP组10.2%(38/373),风险差10.3个百分点(95%CI 5.2至15.4)。
- 高流量治疗未能证明不劣于CPAP,因风险差95%CI下限5.2个百分点未超过预设的10个百分点非劣效界值,但绝对风险差10.3个百分点超过界值。
- 符合方案分析中高流量组治疗失败率14.5%(49/339) vs CPAP组8.0%(27/338),风险差6.5个百分点(95%CI 1.7至11.2)。
- 机械通气、转至三级新生儿重症监护病房及不良事件的发生率两组无显著差异。
- 高流量治疗失败的新生儿可接受CPAP治疗。
适用人群与场景
- 澳大利亚特殊护理 nurseries 中年龄<24小时、胎龄≥31周、出生体重≥1200g且存在呼吸窘迫的新生儿。
诊断标准与关键阈值
- 主要终点治疗失败定义为随机化后72小时内发生治疗失败。
- 非劣效界值为风险绝对差异10个百分点。
处置流程与药物剂量
- 随机分配至经鼻高流量治疗或经鼻持续气道正压通气(CPAP)。
- 经鼻高流量治疗失败的新生儿可接受CPAP治疗。
研究设计与关键结果
- 多中心、随机、非劣效性试验,纳入754例新生儿(平均胎龄36.9周,平均出生体重2909g)进行主要意向性治疗分析。
- 高流量组381例中78例(20.5%)治疗失败,CPAP组373例中38例(10.2%)治疗失败,风险差10.3个百分点(95%CI 5.2至15.4)。
- 符合方案分析:高流量组339例中49例(14.5%)失败,CPAP组338例中27例(8.0%)失败,风险差6.5个百分点(95%CI 1.7至11.2)。
- 机械通气、转至三级新生儿重症监护病房及不良事件的发生率两组无显著差异。
证据类型、等级与局限
- 证据类型:多中心、随机、非劣效性试验。
- 结论:经鼻高流量治疗未能证明不劣于CPAP,在非三级特殊护理 nurseries 中作为呼吸窘迫新生儿的早期呼吸支持时,治疗失败发生率显著高于CPAP。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在非三级特殊护理 nurseries 中,对呼吸窘迫新生儿(胎龄≥31周、出生体重≥1200g、年龄<24小时)选择早期呼吸支持时,经鼻高流量治疗与CPAP相比治疗失败率更高,该试验结果不支持将经鼻高流量治疗作为CPAP的等效替代。
- 经鼻高流量治疗失败的新生儿可转为CPAP治疗。
- 机械通气、转至三级新生儿重症监护病房及不良事件发生率两组无显著差异。
指南或共识出处
- HUNTER试验,澳大利亚与新西兰临床试验注册号 ACTRN12614001203640,由澳大利亚国家健康与医学研究委员会和莫纳什大学资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nasal high-flow therapy is an alternative to nasal continuous positive airway pressure (CPAP) as a means of respiratory support for newborn infants. The efficacy of high-flow therapy in nontertiary special care nurseries is unknown.
METHODS: We performed a multicenter, randomized, noninferiority trial involving newborn infants (<24 hours of age; gestational age, ≥31 weeks) in special care nurseries in Australia. Newborn infants with respiratory distress and a birth weight of at least 1200 g were assigned to treatment with either high-flow therapy or CPAP. The primary outcome was treatment failure within 72 hours after randomization. Infants in whom high-flow therapy failed could receive CPAP. Noninferiority was determined by calculating the absolute difference in the risk of the primary outcome, with a noninferiority margin of 10 percentage points.
RESULTS: A total of 754 infants (mean gestational age, 36.9 weeks, and mean birth weight, 2909 g) were included in the primary intention-to-treat analysis. Treatment failure occurred in 78 of 381 infants (20.5%) in the high-flow group and in 38 of 373 infants (10.2%) in the CPAP group (risk difference, 10.3 percentage points; 95% confidence interval [CI], 5.2 to 15.4). In a secondary per-protocol analysis, treatment failure occurred in 49 of 339 infants (14.5%) in the high-flow group and in 27 of 338 infants (8.0%) in the CPAP group (risk difference, 6.5 percentage points; 95% CI, 1.7 to 11.2). The incidences of mechanical ventilation, transfer to a tertiary neonatal intensive care unit, and adverse events did not differ significantly between the groups.
CONCLUSIONS: Nasal high-flow therapy was not shown to be noninferior to CPAP and resulted in a significantly higher incidence of treatment failure than CPAP when used in nontertiary special care nurseries as early respiratory support for newborn infants with respiratory distress. (Funded by the Australian National Health and Medical Research Council and Monash University; HUNTER Australian and New Zealand Clinical Trials Registry number, ACTRN12614001203640.).
参考来源
- Manley BJ, Arnolda GRB, Wright IMR, et al. Nasal High-Flow Therapy for Newborn Infants in Special Care Nurseries. N Engl J Med. 2019. PMID: 31116919. doi:10.1056/NEJMoa1812077
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。